CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors
WISTV,
SOURCE CSL Behring KING OF PRUSSIA, Pa. Cardiovascular disease is the leading cause of death globally, with an estimated 800,000…